copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
ACRO Health The Association of Clinical Research Organizations (ACRO) represents the leading clinical research and technology companies around the world In our newsletter, we bring you updates on our work and the impact that we are having in advancing the global clinical research industry
ACRO Announces 2025 Officers and New Members WASHINGTON, DC – Washington DC – ACRO today announced that its Board of Directors elected Jim Reilly, Executive Vice President, Development Cloud Strategy at Veeva, as Chair of the Association, effective January 1, 2025
New Report: ACRO Members’ Impact on the Industry ‣ ACRO In early 2025, ACRO conducted a survey of its clinical research organization (CRO) and clinical technology organization (CTO) member companies to better understand their activities and demographic make-up in 2024
Good Clinical Podcast – Season 3, Episode 7: The Impact of ICH E6(R3) In ACRO and TransCelerate BioPharma’s latest collaboration, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week’s episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical
FDA Changes and Implications: What You Need to Know ‣ ACRO The Association of Clinical Research Organizations (ACRO) represents the leading clinical research and technology companies around the world In our newsletter, we bring you updates on our work and the impact that we are having in advancing the global clinical research industry
Our Mission - ACRO Founded in 2002, ACRO represents the world’s leading clinical research and technology organizations, which provide specialized services that are integral to the development of drugs, biologics and medical devices
ACRO Releases Publication Showcasing Benefits of Centralized Monitoring . . . WASHINGTON, DC – Today, ACRO’s RBQM Working Group has announced the publication of its latest RBM RBQM paper, Risk-Based Quality Management: A Case for Centralized Monitoring, in DIA’s Therapeutic Innovation Regulatory Science journal
Acceptable Ranges for Clinical Trials: Insights from ICH E6 (R3) - ACRO The Acceptable Ranges Considerations tool, designed to support stakeholders’ internal development and implementation of acceptable ranges under the ICH E6(R3) guideline, details the introduction of acceptable ranges and comparison to E6(R2), key considerations and tips for implementation, and sample use case
Expedited Program for Serious Conditions—Accelerated Approval of Drugs . . . This comment letter, submitted by ACRO to FDA in 2025 about the Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics can be found below As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators